Cargando…

Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control

BACKGROUND: GLP-1 receptor agonists (GLP-1RA) are increasingly used to treat adolescent obesity. However, the effect on endogenous GLP-1 secretory patterns following treatment in adolescents is unknown. The GLP-1RA exenatide was shown to significantly lower BMI and 2-hour glucose in adolescents with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stenlid, Rasmus, Cerenius, Sara Y., Wen, Quan, Aydin, Banu Küçükemre, Manell, Hannes, Chowdhury, Azazul, Kristinsson, Hjalti, Ciba, Iris, Gjessing, Erik S., Mörwald, Katharina, Gomahr, Julian, Heu, Verena, Weghuber, Daniel, Forslund, Anders, Bergsten, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646558/ https://www.ncbi.nlm.nih.gov/pubmed/38027106 http://dx.doi.org/10.3389/fendo.2023.1293093

Ejemplares similares

Metformin Can Attenuate Beta-Cell Hypersecretion—Implications for Treatment of Children with Obesity
por: Wen, Quan, et al.
Publicado: (2023)

High levels of FSH before puberty are associated with increased risk of metabolic syndrome during pubertal transition
por: Aydin, Banu Kucukemre, et al.
Publicado: (2022)

Low Fasting Concentrations of Glucagon in Patients with Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
por: Stenlid, Rasmus, et al.
Publicado: (2023)

Altered mitochondrial metabolism in peripheral blood cells from patients with inborn errors of β‐oxidation
por: Stenlid, Rasmus, et al.
Publicado: (2021)

Association between Metabolic Syndrome Diagnosis and the Physical Activity—Sedentary Profile of Adolescents with Obesity: A Complementary Analysis of the Beta-JUDO Study
por: Julian, Valérie, et al.
Publicado: (2021)

Combined lipidomic and proteomic analysis of isolated human islets exposed to palmitate reveals time-dependent changes in insulin secretion and lipid metabolism
por: Roomp, Kirsten, et al.
Publicado: (2017)

Determinants of hyperglucagonemia in pediatric non-alcoholic fatty liver disease
por: Maruszczak, Katharina, et al.
Publicado: (2022)

Deviating glucose results in an international dual-center study. A root cause investigation
por: Cadamuro, Janne, et al.
Publicado: (2021)

Single Point Insulin Sensitivity Estimator in Pediatric Non-Alcoholic Fatty Liver Disease
por: Furthner, Dieter, et al.
Publicado: (2022)

Brown adipose tissue estimated with the magnetic resonance imaging fat fraction is associated with glucose metabolism in adolescents
por: Lundström, Elin, et al.
Publicado: (2019)

Serum Ferritin Correlates With Liver Fat in Male Adolescents With Obesity
por: Mörwald, Katharina, et al.
Publicado: (2020)

The Role of Protein and Fat Intake on Insulin Therapy in Glycaemic Control of Paediatric Type 1 Diabetes: A Systematic Review and Research Gaps
por: Furthner, Dieter, et al.
Publicado: (2021)

Basal hypersecretion of glucagon and insulin from palmitate-exposed human islets depends on FFAR1 but not decreased somatostatin secretion
por: Kristinsson, H., et al.
Publicado: (2017)

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
por: Razavi, Michael, et al.
Publicado: (2022)

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes
por: Ridge, T, et al.
Publicado: (2012)

Pancreatic Fat Is Associated With Metabolic Syndrome and Visceral Fat but Not Beta-Cell Function or Body Mass Index in Pediatric Obesity
por: Staaf, Johan, et al.
Publicado: (2017)

The Role of Macronutrients in the Pathogenesis, Prevention and Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) in the Paediatric Population—A Review
por: Pixner, Thomas, et al.
Publicado: (2022)

The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism
por: Andreozzi, Francesco, et al.
Publicado: (2016)

The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial
por: Mitchell, James L, et al.
Publicado: (2023)

Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages
por: Bułdak, Łukasz, et al.
Publicado: (2015)

Long-Acting GLP-1 Receptor Agonist Exenatide Influence on the Autonomic Cardiac Sympatho-Vagal Balance
por: Cacciatori, Vittorio, et al.
Publicado: (2017)

Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide
por: Pinkney, Jonathan, et al.
Publicado: (2010)

The effect of the GLP‐1 analogue Exenatide on functional connectivity within an NTS‐based network in women with and without obesity
por: Coveleskie, K., et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus
por: Capel, Margarita, et al.
Publicado: (2019)

The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: A Danish nationwide cohort study
por: Al-Mashhadi, Zheer Kejlberg, et al.
Publicado: (2022)

Exploring the GLP-1–GLP-1R axis in porcine pancreas and gastrointestinal tract in vivo by ex vivo autoradiography
por: Manell, Elin, et al.
Publicado: (2021)

Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective
por: Brown, Dominique Xavier, et al.
Publicado: (2012)

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
por: Schernthaner, Guntram, et al.
Publicado: (2014)

Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes
por: Aung, Myo Myo, et al.
Publicado: (2019)

Automated segmentation of human cervical-supraclavicular adipose tissue in magnetic resonance images
por: Lundström, Elin, et al.
Publicado: (2017)

From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy
por: Dicembrini, Ilaria, et al.
Publicado: (2011)

Therapeutic stimulation of GLP-1 and GIP protein with DPP-4 inhibitors for type-2 diabetes treatment
por: Sharma, Alok, et al.
Publicado: (2015)

The effect of DPP-4-protected GLP-1 (7–36) on coronary microvascular function in obese adults
por: Nilsson, Malin, et al.
Publicado: (2019)

Detection of Impaired Cognitive Function in Rat with Hepatosteatosis Model and Improving Effect of GLP-1 Analogs (Exenatide) on Cognitive Function in Hepatosteatosis
por: Erbaş, Oytun, et al.
Publicado: (2014)

The GLP-1 Receptor Agonist Exenatide Ameliorates Bone Composition and Tissue Material Properties in High Fat Fed Diabetic Mice
por: Mansur, Sity Aishah, et al.
Publicado: (2019)

Children with Hashimoto’s Thyroiditis Have Increased Intestinal Permeability: Results of a Pilot Study
por: Küçükemre Aydın, Banu, et al.
Publicado: (2020)

SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
por: El Mouhayyar, Christopher, et al.
Publicado: (2020)

Dihydromyricetin Enhances Exercise-Induced GLP-1 Elevation through Stimulating cAMP and Inhibiting DPP-4
por: Wu, Luting, et al.
Publicado: (2022)

Inhibition of DPP-IV Activity and Stimulation of GLP-1 Release by Gastrointestinally Digested Black Soldier Fly Prepupae
por: Luparelli, Anna Valentina, et al.
Publicado: (2023)

GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
por: Złotek, Magdalena, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_r41h3qldop9u3caag92g8bu9jt